Total Payments
$14,952
2024 Payments
$1,926
Companies
18
Transactions
66
Medicare Patients
944
Medicare Billing
$205,525
Payment Breakdown by Category
Consulting$8,790 (58.8%)
Food & Beverage$2,809 (18.8%)
Travel$2,269 (15.2%)
Research$900.86 (6.0%)
Education$182.99 (1.2%)
Other$0.00 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $8,790 | 4 | 58.8% |
| Food and Beverage | $2,809 | 39 | 18.8% |
| Travel and Lodging | $2,269 | 9 | 15.2% |
| Unspecified | $900.86 | 12 | 6.0% |
| Education | $182.99 | 2 | 1.2% |
Payments by Type
General
$14,052
54 transactions
Research
$900.86
12 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Amgen Inc. | $5,866 | 8 | $0 (2017) |
| GENZYME CORPORATION | $2,868 | 3 | $0 (2023) |
| Janssen Scientific Affairs, LLC | $1,685 | 2 | $0 (2024) |
| Janssen Research & Development, LLC | $1,220 | 10 | $0 (2023) |
| Pharmacyclics LLC, An AbbVie Company | $1,069 | 15 | $0 (2023) |
| Janssen Biotech, Inc. | $346.38 | 4 | $0 (2024) |
| Celgene Corporation | $345.71 | 6 | $0 (2024) |
| Incyte Corporation | $332.47 | 3 | $0 (2023) |
| Novartis Pharmaceuticals Corporation | $261.31 | 3 | $0 (2018) |
| E.R. Squibb & Sons, L.L.C. | $198.11 | 2 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $1,926 | 6 | Janssen Scientific Affairs, LLC ($1,650) |
| 2023 | $1,900 | 21 | Janssen Research & Development, LLC ($1,220) |
| 2022 | $118.78 | 1 | Incyte Corporation ($118.78) |
| 2021 | $98.10 | 1 | GlaxoSmithKline, LLC. ($98.10) |
| 2020 | $2,754 | 2 | GENZYME CORPORATION ($2,754) |
| 2019 | $219.80 | 2 | JAZZ PHARMACEUTICALS INC. ($111.38) |
| 2018 | $1,582 | 19 | Pharmacyclics LLC, An AbbVie Company ($1,026) |
| 2017 | $6,353 | 14 | Amgen Inc. ($5,866) |
All Payment Transactions
66 individual payment records from CMS Open Payments — Page 1 of 3
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/06/2024 | E.R. Squibb & Sons, L.L.C. | — | Food and Beverage | Cash or cash equivalent | $79.00 | General |
| 10/10/2024 | Janssen Scientific Affairs, LLC | TALVEY (Biological) | Consulting Fee | Cash or cash equivalent | $1,650.00 | General |
| Category: Oncology | ||||||
| 09/26/2024 | Janssen Biotech, Inc. | CARVYKTI (Drug) | Food and Beverage | In-kind items and services | $32.76 | General |
| Category: Oncology | ||||||
| 08/27/2024 | Celgene Corporation | — | Food and Beverage | Cash or cash equivalent | $29.17 | General |
| 08/13/2024 | Agios Pharmaceuticals, Inc. | PYRUKYND (Drug) | Food and Beverage | In-kind items and services | $19.69 | General |
| Category: Genetically Defined Disease | ||||||
| 04/30/2024 | Janssen Biotech, Inc. | DARZALEX (Biological), TECVAYLI | Food and Beverage | In-kind items and services | $115.56 | General |
| Category: Oncology | ||||||
| 12/13/2023 | Janssen Biotech, Inc. | DARZALEX (Biological) | Education | In-kind items and services | $83.99 | General |
| Category: Oncology | ||||||
| 11/02/2023 | Janssen Research & Development, LLC | — | Travel and Lodging | Cash or cash equivalent | $82.71 | General |
| 11/02/2023 | Janssen Research & Development, LLC | — | Food and Beverage | Cash or cash equivalent | $32.56 | General |
| 11/02/2023 | Janssen Research & Development, LLC | — | Travel and Lodging | Cash or cash equivalent | $24.12 | General |
| 11/02/2023 | Janssen Research & Development, LLC | — | Food and Beverage | Cash or cash equivalent | $19.80 | General |
| 10/12/2023 | Janssen Research & Development, LLC | — | Food and Beverage | In-kind items and services | $55.08 | General |
| 10/12/2023 | Janssen Research & Development, LLC | — | Food and Beverage | In-kind items and services | $35.40 | General |
| 10/12/2023 | Janssen Research & Development, LLC | — | Food and Beverage | In-kind items and services | $17.70 | General |
| 10/11/2023 | Janssen Research & Development, LLC | — | Travel and Lodging | In-kind items and services | $421.72 | General |
| 10/11/2023 | Janssen Research & Development, LLC | — | Travel and Lodging | In-kind items and services | $268.61 | General |
| 10/11/2023 | Janssen Research & Development, LLC | — | Travel and Lodging | In-kind items and services | $262.08 | General |
| 09/12/2023 | Rigel Pharmaceuticals, Inc. | Rezlidhia (Drug), Tavalisse | Food and Beverage | Cash or cash equivalent | $99.02 | General |
| Category: Acute Myeloid Leukemia | ||||||
| 06/01/2023 | Pharmacyclics LLC, An AbbVie Company | EPKINLY (Drug) | Food and Beverage | In-kind items and services | $25.40 | General |
| Category: ONCOLOGY | ||||||
| 05/16/2023 | Incyte Corporation | JAKAFI (Drug) | Food and Beverage | Cash or cash equivalent | $105.27 | General |
| Category: Hematology/Oncology | ||||||
| 05/15/2023 | Janssen Biotech, Inc. | TECVAYLI (Biological) | Food and Beverage | In-kind items and services | $114.07 | General |
| Category: Oncology | ||||||
| 04/27/2023 | Celgene Corporation | Pomalyst (Drug) | Food and Beverage | Cash or cash equivalent | $30.36 | General |
| Category: Hematology | ||||||
| 02/25/2023 | Kite Pharma, Inc. | Yescarta (Drug) | Food and Beverage | In-kind items and services | $48.00 | General |
| Category: CELLT | ||||||
| 02/14/2023 | Pharmacyclics LLC, An AbbVie Company | IMBRUVICA (Drug) | Food and Beverage | In-kind items and services | $17.35 | General |
| Category: ONCOLOGY | ||||||
| 01/27/2023 | Celgene Corporation | Pomalyst (Drug) | Food and Beverage | Cash or cash equivalent | $18.88 | General |
| Category: Hematology | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| PCYC-1140-IM | Pharmacyclics LLC, An AbbVie Company | $900.86 | 12 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 4 | 83 | 190 | $47,653 | $20,105 |
| 2022 | 5 | 128 | 463 | $135,966 | $32,070 |
| 2021 | 7 | 326 | 960 | $268,420 | $67,092 |
| 2020 | 8 | 407 | 1,207 | $326,217 | $86,259 |
Total Patients
944
Total Services
2,820
Medicare Billing
$205,525
Procedure Codes
24
All Medicare Procedures & Services
24 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 31 | 93 | $22,320 | $9,662 | 43.3% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 16 | 30 | $9,450 | $4,628 | 49.0% |
| 99222 | Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | Facility | 2023 | 25 | 27 | $8,883 | $3,061 | 34.5% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 11 | 40 | $7,000 | $2,754 | 39.3% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 45 | 238 | $54,740 | $12,961 | 23.7% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 27 | 162 | $56,700 | $12,602 | 22.2% |
| 99222 | Initial hospital inpatient care per day, typically 50 minutes | Facility | 2022 | 21 | 24 | $10,200 | $2,468 | 24.2% |
| 99239 | Hospital discharge day management, more than 30 minutes | Facility | 2022 | 24 | 26 | $7,566 | $2,079 | 27.5% |
| 99223 | Initial hospital inpatient care per day, typically 70 minutes | Facility | 2022 | 11 | 13 | $6,760 | $1,960 | 29.0% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2021 | 103 | 516 | $116,916 | $28,206 | 24.1% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2021 | 63 | 259 | $84,215 | $20,542 | 24.4% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2021 | 37 | 39 | $20,140 | $5,925 | 29.4% |
| 99239 | Hospital discharge day management, more than 30 minutes | Facility | 2021 | 56 | 70 | $20,370 | $5,769 | 28.3% |
| 99222 | Initial hospital inpatient care, typically 50 minutes per day | Facility | 2021 | 40 | 44 | $18,525 | $4,262 | 23.0% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Facility | 2021 | 15 | 19 | $4,199 | $1,370 | 32.6% |
| 99221 | Initial hospital inpatient care, typically 30 minutes per day | Facility | 2021 | 12 | 13 | $4,055 | $1,017 | 25.1% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2020 | 101 | 579 | $128,779 | $32,207 | 25.0% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2020 | 71 | 345 | $104,001 | $27,895 | 26.8% |
| 99222 | Initial hospital inpatient care, typically 50 minutes per day | Facility | 2020 | 52 | 65 | $27,002 | $6,830 | 25.3% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2020 | 35 | 37 | $18,771 | $5,800 | 30.9% |
| 99239 | Hospital discharge day management, more than 30 minutes | Facility | 2020 | 60 | 69 | $19,927 | $5,681 | 28.5% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Facility | 2020 | 47 | 65 | $12,415 | $3,530 | 28.4% |
| 99215 | Established patient office or other outpatient, visit typically 40 minutes | Facility | 2020 | 26 | 32 | $9,193 | $2,500 | 27.2% |
| 99205 | New patient office or other outpatient visit, typically 60 minutes | Facility | 2020 | 15 | 15 | $6,129 | $1,816 | 29.6% |
About Dr. Amarendra Neppalli, MD
Dr. Amarendra Neppalli, MD is a Hematology & Oncology healthcare provider based in Charleston, South Carolina. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 04/14/2009. The National Provider Identifier (NPI) number assigned to this provider is 1992948442.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Amarendra Neppalli, MD has received a total of $14,952 in payments from pharmaceutical and medical device companies, with $1,926 received in 2024. These payments were reported across 66 transactions from 18 companies. The most common payment nature is "Consulting Fee" ($8,790).
As a Medicare-enrolled provider, Neppalli has provided services to 944 Medicare beneficiaries, totaling 2,820 services with total Medicare billing of $205,525. Data is available for 4 years (2020–2023), covering 24 distinct procedure/service records.
Ad
Practice Information
- Specialty Hematology & Oncology
- Other Specialties Hematology & Oncology
- Location Charleston, SC
- Active Since 04/14/2009
- Last Updated 03/13/2025
- Taxonomy Code 207RH0003X
- Entity Type Individual
- NPI Number 1992948442
Products in Payments
- Blincyto (Biological) $5,866
- SARCLISA (Biological) $2,754
- TALVEY (Biological) $1,650
- Ibrutinib (Drug) $900.86
- JAKAFI (Drug) $332.47
- DARZALEX (Biological) $234.53
- VYXEOS (Drug) $156.30
- Revlimid (Drug) $132.52
- Imbruvica (Drug) $124.99
- EMPLICITI (Biological) $119.11
- TECVAYLI (Biological) $114.07
- CABLIVI (Biological) $114.02
- NINLARO (Drug) $106.10
- Aliqopa (Drug) $100.20
- Rezlidhia (Drug) $99.02
- BLENREP (Biological) $98.10
- KYMRIAH (Biological) $93.47
- RYDAPT (Drug) $87.23
- TASIGNA (Drug) $80.61
- Pomalyst (Drug) $73.52
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Hematology & Oncology Doctors in Charleston
Mr. George Geils, M.d, M.D
Hematology & Oncology — Payments: $184,021
Hematology & Oncology $184,021
Mr. David Ellison, M.d, M.D
Hematology & Oncology — Payments: $39,035
Hematology & Oncology $39,035
Dr. Albert Lockhart, Md, MD
Hematology & Oncology — Payments: $36,997
Hematology & Oncology $36,997
Dr. Irl Greenwell, M.d, M.D
Hematology & Oncology — Payments: $30,803
Hematology & Oncology $30,803
Dr. Brian Lingerfelt, Md, MD
Hematology & Oncology — Payments: $30,721
Hematology & Oncology $30,721
Robert Stuart, Md, MD
Hematology & Oncology — Payments: $25,933
Hematology & Oncology $25,933